Related Experiment Video
Updated: Mar 8, 2026
09:02
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
22.6K
Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
1Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, 676 N. St Clair, Suite 850, Chicago, IL, 60611, USA.
Current Hematologic Malignancy Reports
|February 4, 2017
Summary
Novel targeted therapies offer new hope for chronic lymphocytic leukemia (CLL) patients, especially those intolerant to chemotherapy or with high-risk genetic mutations. These agents provide durable remissions, addressing previously unmet needs in challenging patient groups.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Chemoimmunotherapy was the traditional standard for chronic lymphocytic leukemia (CLL).
- Limited effective options existed for chemotherapy-intolerant patients or those with 17p deletions.
- Novel targeted agents represent a significant advancement in CLL treatment.
Purpose of the Study:
- To review the role and mechanisms of novel targeted agents in chronic lymphocytic leukemia (CLL) treatment.
- To highlight the potential of these agents for challenging patient populations.
- To discuss the current landscape and future directions for targeted therapy sequencing in CLL.
Main Methods:
- Review of current targeted agents used in chronic lymphocytic leukemia (CLL) treatment.
- Analysis of targeted pathways including B cell receptor-associated tyrosine kinases (BTK, SYK), PI3-kinase pathway, and BCL-2.
- Discussion of patient populations who benefit from targeted therapies.
Main Results:
- Novel targeted agents offer long-term, durable remissions in chronic lymphocytic leukemia (CLL).
- These therapies are effective for patients intolerant to chemotherapy and those with high-risk 17p deletions.
- Targeted agents act on key signaling pathways and proteins crucial for CLL cell survival.
Conclusions:
- Targeted agents provide promising new treatment options for chronic lymphocytic leukemia (CLL).
- The differing side effect profiles may guide therapy selection in the absence of definitive sequencing data.
- Further randomized data is needed to establish optimal sequencing of these novel agents in CLL management.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
60
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
60
01:27Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
01:24Modified-Release Drug Delivery Systems: Site-Targeted
59
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
59